Providence Cancer Center

NEW YORK, May 21, 2024 /PRNewswire/ -- Surgical teams at NYU Langone Health performed the world's first genetically modified pig kidney transplants into a human body in September and November 2021, and then transplanted two pig hearts in the summer of 2022. These procedures were done in patients declared dead based on neurologic criteria (decedents) and maintained on ventilators with the consent of their families. Demonstrating the field's progress, NYU Langone in April 2024 transplanted a pig kidney into a living patient. Now two new analyses, one published online on May 17 in Nature Medicine and the other May 21 in Med, reveal changes at the single-cell level in the organs and recipient's bodies before, during, and just after the xenotransplantation surgeries in the decedents. Teams of scientists had worked alongside the surgeons, taking blood and tissue samples to analyze changes in tens of thousands of collected cells. Led by researchers at NYU Grossman School of Medicine and the Broad Institute of MIT and Harvard, the Med paper tracked the genetic and cellular activity in the two pig kidneys transplanted into humans, and compared them against pig kidney samples that had not been translated. To do so, the research team used several techniques, including single-cell RNA sequencing, which determined the order (sequence) of the molecular letters making up the pig and human genes active in various cell types during the procedures. The study showed that the transplanted pig kidneys, while not rejected outright by the recipients' bodies (no immediate kidney failure), caused a strong reaction in human peripheral blood mononuclear cells (PBMCs). This set of immune cells can attack transplanted (foreign) organs much like they attack foreign invaders, such a viruses. While immediate rejection was not seen, in part due to treatment with medications that suppressed it, the new study found evidence of subtler reactions that could cause xenotransplants to fail over time. Specifically, the pig kidneys were seen to trigger "antibody-mediated rejection" at the molecular level. As the body develops immune proteins called antibodies specific to a transplanted organ, they recruit natural killer cells, macrophages, and T cells that can injure it. The team also saw an uptick in pig kidneys of tissue repair mechanisms, where certain cells multiply as part of the growth involved in healing. Normal cells that transform into cancer cells also grow aggressively, so the mechanism bears watching. "We have detailed the cellular mechanisms that dictate how human immune cells react to a xenotransplant in the short term," said Jef Boeke, PhD, a co-senior author on both studies, and director of the Institute for System Genetics at NYU Grossman School of Medicine. "These results give us new insights into how we might further engineer pig organs for transplant, or tailor immunosuppression treatments to improve tolerance of a foreign organ." By tracking the interplay between the kidneys and human system several times each day, the researchers found that pig kidney immune cells drove reactions right after the transplant, but that human immune cells infiltrated the pig organs by 48 hours to dominate signaling. Measuring the degree to which pig immune cells trigger the first wave of immune attack on xenotransplants will shape efforts to prevent irreversible cellular damage to them, say the study authors. Transplanted Hearts The other new paper, published in Nature Medicine, featured a "multiomics" analysis of pig hearts and surrounding human cells in decedents. This included analyses every six hours after transplant of gene activity (transcriptomics), as well of proteins (proteomics), lipids, and metabolites (intermediates in biological pathways) present in cells. Rapid, massive increases in the number of certain cell types were also seen in decedents receiving pig hearts. In one of the decedents (designated D1) but not the other, activated T cell and natural killer (NK) cell populations within the PBMC group increased from about one percent 30 hours post-transplant to more than 20 percent of the entire PBMC population by 66 hours after the procedure. This dramatic immune reaction to the organ, a complication called perioperative cardiac xenograft dysfunction (PCXD), came with a damaging inrush of immune cells (inflammation), and misplaced healing attempts (tissue remodeling) that thicken tissue and can hinder function. The worse outcomes experienced by the one decedent may be partly because this heart was smaller than anticipated for the recipient's size, and required an extra procedure to compensate for it, the researchers said. These factors may have cut off blood flow and the oxygen supply to the heart for longer, which is known to cause ischemia reperfusion injury when the supply is restored. The research team observed that PCXD-related immune reactions to the pig organ got worse in the presence of this recipient's reperfusion injury. "This study demonstrated that multiomics can be used to reveal a broad picture of what is happening in the recipient of a xenograft," said Brendan Keating, PhD, a co-senior author on both studies and faculty in Department of Surgery at NYU Grossman School of Medicine. "The team that did the xenotransplant had several theories about why the first decedent was having more issues, but multiomics helped to define the complications, and may be used to counter them moving forward." Robert Montgomery, MD, DPhil, the H. Leon Pachter chair of the Department of Surgery at NYU Langone Health was a co-senior author of the kidney paper. This study was also led by co-senior study author Bo Xia, PhD, a graduate student at the time of the study at NYU Grossman School of Medicine, who is now a principal investigator at the Broad Institute of MIT and Harvard. Co-first-authors were Wanqing Pan and Binghan Zheng of Dr. Xia's group at the Broad Institute, and Weimin Zhang of the Institute for Systems Genetics (ISG) at NYU Grossman School of Medicine. Also a Broad Institute author was Jiangshan Bai. Other NYU Langone study authors were Brendan Camellato and Yinan Zhu at ISG; Jeffrey Stern, Elaina Weldon, Jacqueline Kim, Karen Khalil, Massimo Mangiola, and Adam Griesemer in the NYU Langone Transplant Institute; Adriana Heguy and Peter Meyn in the Genome Technology Center; Ziyan Lin and Alireza Khodadadi-Jamayran of the Applied Bioinformatics Laboratories, and Philip Sommer in the Department of Anesthesiology, Perioperative Care & Pain Medicine. Along with Dr. Keating, a corresponding author of the Nature Medicine heart study, co-first authors were Eloi Schmauch and Dr. Xia, Brian Piening of the Providence Cancer Center in Portland, Maedeh Mohebnasab of the Division of the University of Pittsburgh Medical Center, Chenchen Zhu of Stanford University, Dr. Stern, and Weimin Zhang, of the ISG. Also NYU Langone authors were Jacqueline Kim, David Andrijevic, Karen Khalil, Ian Jaffe, Simon Williams, Elaina Weldon, Mercy Williams, Qian Guo, Sophie Widawsky, Vasishta Tatapudi, Massimo Mangiola, Navneet Narula, Nader Moazami, Harvey Pass, Adam Griesemer in the Transplant Institute; Brendan Camellato, Larisa Kagermazova, and Yinan Zhu in the ISG; Feng-Xia Liang, and Joseph Sall in Department of Cell Biology, Adriana Heguy in the Department of Pathology, and Han Chen and Ramin Herati in the Department of Medicine. Additional authors were from the University of Pennsylvania, Stanford University, University of Oxford, Broad Institute, Imam Abdulrahman bin Faisal University in Saudi Arabia, the Paris Institute for Transplantation and Organ Regeneration, Cleveland Clinic, University of Eastern Finland, 10x Genomics, United Therapeutics (which provided funding), and Revivicor, Inc. All authors are listed in the study manuscript. The authors would like to thank the families of the decedents for their generous donation to science, and LiveOnNY for providing end-of-life family support. The kidney work was supported in National Institute of Health grants RM1HG009491 and DP5OD033430. The heart work was supported by National Institute of Health grants R01 AI144522 and P30CA016087. Other funding sources of the heart study were the Orion Research Foundation, Yrjö Jahnsson Foundation; the Vilho, Yrjö and Väisälä Fund; Aarne Koskelon Foundation, and the Antti and Tyyne Soininen Foundation. Dr. Boeke is a founder and consultant of CDI Labs, Inc., Neochromosome, Inc., and ReOpen Diagnostics. He serves or served on the scientific advisory boards of Logomix, Inc., Modern Meadow, Inc., Rome Therapeutics, Inc., Sample6, Inc., Sangamo, Inc., Tessera Therapeutics, Inc. and the Wyss Institute, all unrelated to the present work. Dr. Montgomery is on scientific advisory boards for eGenesis, Sanofi, Regeneron, CareDx and Hansa Biopharma, is a consultant to Recombinetics, and reports consulting fees from Hansa Medical, Regeneron, ThermoFisher Scientific, Genentech, CareDx, One Lambda, ITB Med, Sanofi and PPD Development, all unrelated to the present work. These relationships are being managed in keeping with the policies of NYU Langone Health. Contact: Gregory Williams, [email protected] SOURCE NYU Langone Health System

LAUSANNE, Switzerland--(BUSINESS WIRE)-- Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the appointment of Dr. Carlo Bifulco, an expert in Translational Molecular Pathology and Pathology Informatics, to its Scientific Advisory Board (SAB) to provide strategic advisory support to the company’s scientific activities and product portfolio development. This press release features multimedia. View the full release here: Dr. Carlo Bifulco (Photo: Business Wire) Dr. Bifulco is a Surgical Pathologist with additional fellowship subspecialty training, expertise, and board certification in Molecular Genetic Pathology and Hematopathology. Dr. Bifulco serves on the Global Colon Cancer Immunoscore Task Force led by the Society for Immunotherapy of Cancer (SITC) and is co-Chair of the SITC Pathology Task convened to establish multiplexed immunohistochemistry/immunofluorescence (mIHC/IF) standards. His current translational research is focused on supporting the characterization of the tumor immune microenvironment through immunohistochemical and image analysis techniques, and on the integration of genomics in immuno-oncology. Dr. Bifulco’s role in the SAB will be to bring strategic insights that will enable Lunaphore to become leaders in the field of high-dimensional analysis of histopathological samples and to support the company in the establishment of scientific partnerships with key stakeholders in coming years. “We are very excited to have Dr. Bifulco join us as we seek to bring our microfluidic-based platforms to the next-level.” noted Dr. Dupouy, CTO at Lunaphore. “Dr. Bifulco is an innovative Pathologist, whose insights will be invaluable for Lunaphore to harness the potential of multiplexed immunofluorescence in the field of translational research as well as to provide us with a better understanding of US-focused clinical practices, even more so in this era of cancer immunotherapy”. “I am very excited by Lunaphore’s microfluidic technological advances, aiming to improve speed, reliability, reproducibility and accuracy of tissue-based biomarker testing”, said Dr. Bifulco. “Physician decision-making in personalized medicine needs robust biomarkers, and solutions such as Lunaphore’s Fast-Fluidic Exchange (FFeX) may become instrumental to improving patient outcomes”. Dr. Bifulco currently serves as the Director of Molecular Pathology and Pathology Informatics at Providence, and as the Director of Translational Molecular Pathology and Molecular Genomics at the Earle A. Chiles Research Institute in Portland, Oregon, a division of the Providence Cancer Institute. He oversees the Province System Molecular Genomics Laboratory, one of the largest clinical genomics labs in the Pacific Northwest, which provides state-of-the-art genomic sequencing to cancer patients across the seven-state system. Prior to joining Providence, Dr. Bifulco served on the Pathology faculty at the National Cancer Center in Milan, at the University of Florida and at Yale University, and completed fellowships in Hematopathology at Yale and in Oncologic Surgical Pathology and Molecular Genetic Pathology at Memorial Sloan Kettering Cancer Center. About Lunaphore Lunaphore Technologies S.A. is a Swiss company transforming the field of tissue analytics in cancer research through the development of innovative staining and imaging technology platforms. The award-winning technology at its core is called FFeX (Fast Fluidic Exchange). Using high-precision microfluidics, complex assays can be automated, extracting comprehensive data much faster than current techniques. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue analytics and has been recognized as one of the most innovative companies internationally. For further information on Lunaphore and its products, please visit .